Subscribe to Email Alerts
Menu
About Us
About INOVIQ
Market Opportunity
Board
The Team
Partners
Distributors
Compliance
Careers
Technology
Our Science
NETs Platform
SubB2M Platform
BARD1 Biomarker Technology
hTERT ICC Assay
Intellectual Property
Publications
Resources
Business Development
Products
Our Products
EXO-NET® Pan-Exosome
Product Overview
Technical Information
Data & Figures
Ordering
hTERT ICC Test
Pipeline
Development Pipeline
SubB2M CA15-3
SubB2M CA125
Exo-Ovarian Cancer Test
Exosome Therapeutics
Investors
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
News & Events
INOVIQ in the News
Conferences & Events
Contact
Contact Us
Subscribe to Email Alerts
ASX Announcements
Heading &
Sub-heading can be edited through HQI
Investors
>
ASX Announcements
Investor Overview
ASX Announcements
Annual & Financial Reports
Presentations
Share Price Information
AGM
INOVIQ Fact Sheet
Corporate Governance
Shareholder Services
FAQ
Analyst Reports
ASX Announcements
Filter by Year:
2024
2023
2022
2021
2020
2019
2018
6-Apr-2022
Updated Investor Presentation
6-Apr-2022
SubB2M Paper Published in BMC Cancer Journal
5-Apr-2022
INOVIQ Engages ResearchDX to Develop & Validate SubB2M-Tests
1-Apr-2022
INOVIQ & UQ Collaborate on Exosome-based Ovarian Cancer Test
28-Mar-2022
Update on Legal Proceedings and BARD1 Autoantibody Program
25-Feb-2022
Appendix 4D and Half Year Financial Report
23-Feb-2022
Brazilian Patent Issued for Lung & Colorectal Cancer
3-Feb-2022
Updated Investor Presentation
31-Jan-2022
Notification regarding unquoted securities - IIQ
31-Jan-2022
Appendix 4C & Quarterly Activities Report
Previous
1
2
3
4
5
6
Next